The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Injectable Peptides Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Brand
1.2.3 Generic Drug
1.3 Market by Application
1.3.1 Global Injectable Peptides Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Injectable Peptides Market Perspective (2018-2029)
2.2 Injectable Peptides Growth Trends by Region
2.2.1 Global Injectable Peptides Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Injectable Peptides Historic Market Size by Region (2018-2023)
2.2.3 Injectable Peptides Forecasted Market Size by Region (2024-2029)
2.3 Injectable Peptides Market Dynamics
2.3.1 Injectable Peptides Industry Trends
2.3.2 Injectable Peptides Market Drivers
2.3.3 Injectable Peptides Market Challenges
2.3.4 Injectable Peptides Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Injectable Peptides Players by Revenue
3.1.1 Global Top Injectable Peptides Players by Revenue (2018-2023)
3.1.2 Global Injectable Peptides Revenue Market Share by Players (2018-2023)
3.2 Global Injectable Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Injectable Peptides Revenue
3.4 Global Injectable Peptides Market Concentration Ratio
3.4.1 Global Injectable Peptides Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Injectable Peptides Revenue in 2022
3.5 Injectable Peptides Key Players Head office and Area Served
3.6 Key Players Injectable Peptides Product Solution and Service
3.7 Date of Enter into Injectable Peptides Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Injectable Peptides Breakdown Data by Type
4.1 Global Injectable Peptides Historic Market Size by Type (2018-2023)
4.2 Global Injectable Peptides Forecasted Market Size by Type (2024-2029)
5 Injectable Peptides Breakdown Data by Application
5.1 Global Injectable Peptides Historic Market Size by Application (2018-2023)
5.2 Global Injectable Peptides Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Injectable Peptides Market Size (2018-2029)
6.2 North America Injectable Peptides Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Injectable Peptides Market Size by Country (2018-2023)
6.4 North America Injectable Peptides Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Injectable Peptides Market Size (2018-2029)
7.2 Europe Injectable Peptides Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Injectable Peptides Market Size by Country (2018-2023)
7.4 Europe Injectable Peptides Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Injectable Peptides Market Size (2018-2029)
8.2 Asia-Pacific Injectable Peptides Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Injectable Peptides Market Size by Region (2018-2023)
8.4 Asia-Pacific Injectable Peptides Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Injectable Peptides Market Size (2018-2029)
9.2 Latin America Injectable Peptides Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Injectable Peptides Market Size by Country (2018-2023)
9.4 Latin America Injectable Peptides Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Injectable Peptides Market Size (2018-2029)
10.2 Middle East & Africa Injectable Peptides Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Injectable Peptides Market Size by Country (2018-2023)
10.4 Middle East & Africa Injectable Peptides Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Injectable Peptides Introduction
11.1.4 Sanofi Revenue in Injectable Peptides Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Injectable Peptides Introduction
11.2.4 Teva Revenue in Injectable Peptides Business (2018-2023)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Detail
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Injectable Peptides Introduction
11.3.4 Novo Nordisk Revenue in Injectable Peptides Business (2018-2023)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Injectable Peptides Introduction
11.4.4 Takeda Revenue in Injectable Peptides Business (2018-2023)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Detail
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Injectable Peptides Introduction
11.5.4 Eli Lilly Revenue in Injectable Peptides Business (2018-2023)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Injectable Peptides Introduction
11.6.4 AstraZeneca Revenue in Injectable Peptides Business (2018-2023)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Injectable Peptides Introduction
11.7.4 Novartis Revenue in Injectable Peptides Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Injectable Peptides Introduction
11.8.4 AbbVie Revenue in Injectable Peptides Business (2018-2023)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Detail
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Injectable Peptides Introduction
11.9.4 Ipsen Revenue in Injectable Peptides Business (2018-2023)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Detail
11.10.2 Ferring Business Overview
11.10.3 Ferring Injectable Peptides Introduction
11.10.4 Ferring Revenue in Injectable Peptides Business (2018-2023)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Injectable Peptides Introduction
11.11.4 Merck Revenue in Injectable Peptides Business (2018-2023)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Detail
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Injectable Peptides Introduction
11.12.4 The Medicines Revenue in Injectable Peptides Business (2018-2023)
11.12.5 The Medicines Recent Development
11.13 Roche
11.13.1 Roche Company Detail
11.13.2 Roche Business Overview
11.13.3 Roche Injectable Peptides Introduction
11.13.4 Roche Revenue in Injectable Peptides Business (2018-2023)
11.13.5 Roche Recent Development
11.14 J & J
11.14.1 J & J Company Detail
11.14.2 J & J Business Overview
11.14.3 J & J Injectable Peptides Introduction
11.14.4 J & J Revenue in Injectable Peptides Business (2018-2023)
11.14.5 J & J Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details